New software aims to make liver cancer ablation more precise
NCT ID NCT04083378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a software-aided imaging system (Morfeus) can help doctors confirm that liver tumors are fully covered during ablation. About 107 patients with up to 3 liver tumors will be treated with standard ablation, and the software will be used to assess the ablation margin. The goal is to see if this approach reduces the chance of tumor regrowth compared to the usual visual inspection of CT scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Software-aided imaging (Morfeus)
- What this could lead to
- If successful, this could lead to more accurate liver tumor ablation, potentially reducing the chance of cancer returning after treatment.
- What could go wrong
- This is a phase 2 trial with only 107 participants, so results may not apply to everyone. The software may not improve outcomes significantly over standard methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT LIVER NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States